Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4406-4414

  Ohlsson, Claes ^b   Labrie, Fernand ^c   Barrett Connor, Elizabeth ^d   Karlsson, Magnus K ^e   Ljunggren, Östen ^f   Vandenput, Liesbeth ^b   Mellström, Dan ^b   Tivesten, Åsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LUND UNIVERSITY   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

AGE DISTRIBUTION; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEATH; DISEASE REGISTRY; ESTRADIOL BLOOD LEVEL; FOLLOW UP; GAS LIQUID CHROMATOGRAPHY; GERIATRIC PATIENT; HUMAN; HYPOTHESIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MORTALITY; NEOPLASM; PRIORITY JOURNAL; SWEDEN; TESTOSTERONE BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT ANALYSIS; DOWN REGULATION; EPIDEMIOLOGY; PHYSIOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DOWN-REGULATION; HUMANS; MALE; RISK FACTORS; SWEDEN;

EID: 77956598914     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0760     Document Type: Article

References (40)

1. Labrie F, Luu-The V, Bëlanger A, Lin SX, Simard J, Pelletier G, Labrie C 2005 Is dehydroepiandrosterone a hormone? J Endocrinol 187:169-196
2. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK 2006 The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 38:89-116
3. Tchernof A, Labrie F 2004 Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151:1-14
4. Bhagra S, Nippoldt TB, Nair KS 2008 Dehydroepiandrosterone in adrenal insufficiency and ageing. Curr Opin Endocrinol Diabetes Obes 15:239-243
5. Arlt W, Hewison M 2004 Hormones and immune function: implications of aging. Aging Cell 3:209-216
6. Dillon JS 2005 Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 4:377-385
7. Chen CC, Parker Jr CR 2004 Adrenal androgens and the immune system. Semin Reprod Med 22:369-377
8. Barrett-Connor E, Khaw KT, Yen SS 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524
9. Trivedi DP, Khaw KT 2001 Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 86:4171-4177
10. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE 1996 Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA 93:13410-13415
11. Mazat L, Lafont S, Berr C, Debuire B, Tessier JF, Dartigues JF, Baulieu EE 2001 Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci USA 98:8145-8150
12. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L 2007 Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 167:2249-2254
13. Barrett-Connor E, Goodman-Gruen D 1995 The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 774:259-270
14. Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B, Baulieu EE 1995 Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 41:343-351
15. Tilvis RS, Kähönen M, Härkönen M 1999 Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano) 11:30-34
16. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB 2001 Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 153:79-89
17. Kähönen MH, Tilvis RS, Jolkkonen J, Pitkälä K, Härkönen M 2000 Predictors and clinical significance of declining plasma dehydroepiandrosterone sulfate in old age. Aging 12:308-314
18. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C 2009 Lows erum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482-2488
19. Breslow NE, Day NE 1987 Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ: 1-406
20. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS 2004 Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:534-543
21. La Croix AZ, Yano K, Reed DM 1992 Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86:1529-1535
22. Slowinska-Srzednicka J, Zgliczyński S, Ciświcka-Sznajderman M, Srzednicki M, Soszyński P, Biernacka M, Woroszylska M, Ruzyllo W, Sadowski Z 1989 Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 79:197-203
23. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC 1994 Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 89:89-93
24. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM 1990 Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460-470
25. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ 1994 Dehydroepiandrosterone sulfate and the risk of myocardial infarction in U.S. male physicians: a prospective study. Am J Epidemiol 140:870-875
26. 4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 19:1045-1050
27. Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino Sr RB, Bhasin S, Vasan RS 2006 Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 145:176-184
28. Altman R, Motton DD, Kota RS, Rutledge JC 2008 Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARα and NF-κB. Vascul Pharmacol 48:76-84
29. Poynter ME, Daynes RA 1998 Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841
30. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 84:813-819
31. Burnand B, Feinstein AR 1992 The role of diagnostic inconsistency in changing rates of occurrence for coronary heart disease. J Clin Epidemiol 45:929-940
32. Marx C, Petros S, Bornstein SR, Weise M, Wendt M, Menschikowski M, Engelmann L, Höffken G 2003 Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, and cortisol. Crit Care Med 31:1382-1388
33. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H 2003 Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88:3190-3195
34. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, Funder JW, Sudhir K, Komesaroff PA 2004 Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 89:4708-4715
35. Christiansen JJ, Andersen NH, Sorensen KE, Pedersen EM, Bennett P, Andersen M, Christiansen JS, Jorgensen JO, Gravholt CH 2007 Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol (Oxf) 66:426-433
36. Rice SP, Agarwal N, Bolusani H, Newcombe R, Scanlon MF, Ludgate M, Rees DA 2009 Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab 94:1966-1972
37. Villareal DT, Holloszy JO 2004 Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292:2243-2248
38. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton 3rd LJ, Smith GE, Khosla S, Jensen MD 2006 DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355:1647-1659
39. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM 2006 Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91:2986-2993
40. von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R 2008 Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 19:699-707